Dr. Sander S. Florman

Dr. Florman oversees an integrated transplant-oncology service that marries surgical innovation with translational research at Mount Sinai’s Icahn School of Medicine. He guides clinical, educational, and investigative agendas that span organ preservation, immunomodulation, and transplant eligibility for patients with advanced liver malignancies.

 

His scholarship examines donor-organ optimization, living-donor safety, and tumor-downstaging before transplantation. Recent multicenter studies explore normothermic machine perfusion, viral-positive graft utilization, and immunotherapy bridging strategies, each designed to expand the donor pool while safeguarding graft survival. Findings inform consensus statements on enhanced-recovery protocols and peri-operative risk prediction that influence global practice.

 

Consultations emphasize clear, jargon-free dialogue. Multidisciplinary teams review imaging, pathology, and genomic data alongside quality-of-life considerations so that individuals of varied educational backgrounds grasp surgical options, potential complications, and research alternatives. This balanced approach sustains high trial enrollment and fosters trust across culturally diverse patient populations.